New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
|Articles|May 1, 2012
- BioPharm International-05-01-2013
- Volume 26
- Issue 5
BioPharm International, May 2012 Issue (PDF)
Monoclonal Antibodies : Developing an Alternative Polishing Step
Advertisement
Articles in this issue
over 13 years ago
Regulatory Convergence Sought for Global Pharma Marketover 13 years ago
Measuring Protein Mobility with Electrophoretic Light Scatteringover 13 years ago
Data and Systems Managementover 13 years ago
Report from Brazilover 13 years ago
The Future of Valves and Diaphragms Supplyover 13 years ago
Extractables and Leachables: Best Practices to Ensure Patient Safetyover 13 years ago
Facility Trends: Modularization and Single UseAdvertisement
Related to this article
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Advertisement
Advertisement